Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group

BACKGROUND: Even clearly resectable pancreatic cancer still has an unfavorable prognosis. Neoadjuvant or perioperative therapies might improve the prognosis of these patients. Thus, evaluation of perioperative chemotherapy in resectable pancreatic cancer in a prospective, randomized trial is warrant...

Descripción completa

Detalles Bibliográficos
Autores principales: Ettrich, Thomas J., Berger, Andreas W., Perkhofer, Lukas, Daum, Severin, König, Alexander, Dickhut, Andreas, Wittel, Uwe, Wille, Kai, Geissler, Michael, Algül, Hana, Gallmeier, Eike, Atzpodien, Jens, Kornmann, Marko, Muche, Rainer, Prasnikar, Nicole, Tannapfel, Andrea, Reinacher-Schick, Anke, Uhl, Waldemar, Seufferlein, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311014/
https://www.ncbi.nlm.nih.gov/pubmed/30594153
http://dx.doi.org/10.1186/s12885-018-5183-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311014/
https://www.ncbi.nlm.nih.gov/pubmed/30594153
http://dx.doi.org/10.1186/s12885-018-5183-y

Ejemplares similares